Tesamorelin Spray is an innovative nasal spray formulation of tesamorelin. As a synthetic analog of growth hormone-releasing hormone (GHRH), it reshapes the traditional administration experience with its non-invasive advantages. The core mechanism of action of this formulation is to mimic endogenous GHRH, precisely activate pituitary receptors, and stimulate the pulsatile secretion of growth hormone (GH)-rather than providing exogenous GH supplementation.
Its core clinical efficacy lies in the targeted reduction of visceral fat, making it particularly suitable for patients with HIV-associated lipodystrophy. Meanwhile, it can improve lipid profiles and insulin sensitivity, and also exhibits potential anti-aging and cognitive support effects. With its mild mode of action and convenient dosage form, it not only retains tesamorelin's advantage in precise body composition regulation but also addresses the usability pain points of traditional injections.
Our Products Form
Tesamorelin COA
The core goal of healthy aging is to delay the decline of physiological functions, maintain bodily homeostasis, reduce the incidence of age-related diseases, and thereby extend healthspan. With the in-depth exploration of aging mechanisms, the functional decline of the growth hormone axis has been identified as one of the key drivers of the aging process. As an innovative nasal spray formulation of GHRH analog, Tesamorelin Spray demonstrates unique potential in healthy aging and longevity research due to its advantages in physiological regulation and non-invasive administration. By precisely activating the pulsatile secretion of GH, it targets and ameliorates age-related metabolic disorders, sarcopenia, abnormal fat accumulation, and other issues, providing an important tool for exploring scientific anti-aging approaches.
Key Research Directions: Focusing on the Regulation of Core Healthy Aging Phenotypes
Age-related body composition disorders, especially excessive visceral fat accumulation and muscle loss, are important predisposing factors for geriatric diseases such as metabolic syndrome and cardiovascular diseases, and are also key determinants of reduced healthspan. Unlike traditional weight-loss drugs, it has demonstrated the unique advantage of "targeted fat reduction, muscle preservation and hypertrophy" in studies: by activating the GH-IGF-1 pathway to enhance fatty acid oxidation, it specifically reduces abdominal visceral fat without affecting subcutaneous fat distribution, avoiding problems such as skin sagging and sudden metabolic rate drop caused by fat atrophy.
Meanwhile, it can promote muscle protein synthesis, increase lean body mass, and improve sarcopenia in the elderly population-a characteristic that has been confirmed in multiple clinical studies.
Compared with the side effect of lean muscle loss associated with some weight-loss drugs such as GLP-1 receptor agonists, Tesamorelin's advantage of reducing fat while maintaining muscle mass has made it a key direction in metabolic aging intervention research, providing a new approach for middle-aged and elderly populations to maintain metabolic homeostasis and delay the aging process.
Research on the Maintenance of Physiological Functions and Improvement of Quality of Life in the Elderly
Healthy aging not only pursues lifespan extension but also emphasizes the integrity of physiological functions and the improvement of quality of life in old age. By regulating the function of the growth hormone axis, the product can simultaneously improve multiple physiological decline indicators: at the level of energy metabolism, it can increase basal metabolic rate and alleviate age-related fatigue and lassitude; at the level of cognitive function, activation of the GH-IGF-1 pathway can promote neuronal repair and neurotransmitter synthesis, with preliminary studies showing its potential role in delaying age-related cognitive decline; at the level of motor function, increased muscle mass and improved muscle function can enhance mobility and reduce the risks of falls and motor limitations.
The product intervention can significantly improve the physical endurance, sleep quality, and emotional state of subjects, which is closely related to the enhanced body repair capacity induced by increased GH secretion. The convenience of its nasal spray dosage form also provides feasibility for long-term intervention studies, being particularly suitable for independent operation by middle-aged and elderly subjects, avoiding the impact of injection dosage forms on research compliance, and laying the foundation for exploring long-term anti-aging intervention programs.
Research on the Prevention of Age-related Complications
One of the core goals of longevity research is to reduce the incidence of age-related complications. Through improving metabolic disorders and inhibiting chronic inflammation, it has shown potential in the research on prevention of age-related complications. As a "metabolically active endocrine organ", visceral fat secretes a large number of inflammatory factors that induce chronic inflammation, accelerating the progression of diseases such as atherosclerosis and fatty liver. The targeted visceral fat-clearing effect of it can significantly reduce inflammatory factor levels, delay systemic chronic inflammatory responses, and provide an intervention target for preventing geriatric cardiovascular diseases and non-alcoholic fatty liver disease.
Advantages of Dosage Form Research: Empowering the Exploration of Long-term Healthy Aging Interventions
Healthy aging and longevity research mostly require long-term intervention and follow-up, and dosage form characteristics directly affect research feasibility and subject compliance. The dosage form advantages of Tesamorelin Spray provide key support for such research. Compared with traditional injection formulations, the nasal spray administration completely avoids problems such as needle phobia and injection site reactions, achieving higher subject acceptance.
From a pharmacokinetic perspective, after absorption through the nasal mucosa, it can resist cleavage mediated by dipeptidyl peptidase IV, with significantly higher stability than endogenous GHRH. Its half-life is extended to approximately 30 minutes, and biological activity can last for 6–8 hours, enabling stable maintenance of pulsatile GH secretion and avoiding adverse effects of drastic hormone level fluctuations on the elderly body.
Manufacturing Process Flow
Raw Material Synthesis and Purification
Solid-phase peptide synthesis (SPPS) technology is adopted to construct the peptide chain by adding amino acids one by one. Finally, reversed-phase high-performance liquid chromatography (RP-HPLC) is used for purification to remove impurities and unreacted monomers.
After purification, lyophilization is required to obtain the white or off-white powdered active pharmaceutical ingredient (API), with moisture content ≤ 5.0% and loss on drying ≤ 1.0%.
Excipient Selection and Formulation Optimization
Stabilizers:
Such as hydroxypropyl-β-cyclodextrin (HP-β-CD), used to improve the solubility and chemical stability of Tesamorelin in solution and prevent degradation.
Penetration enhancers:
Such as polysorbate 80 or bile salt compounds, which can disrupt the tight junctions of the nasal mucosa and promote transdermal drug absorption.
pH regulators:
Hydrochloric acid or sodium hydroxide is used to adjust the solution pH to 4.5–6.5, so as to match the physiological environment of the nasal mucosa and reduce irritation.
Formulation Preparation
Dissolve the API and excipients in water for injection or buffer solution in a specific ratio, and perform sterile filtration through a 0.22μm filter membrane.
Adopt high-pressure homogenization technology to ensure uniform particle size distribution (D₅₀ ≤ 10μm) and avoid spray nozzle clogging.
Fill the solution into nasal spray devices, with the dosage per spray precisely controlled (usually 0.1–0.2mL per spray) to ensure that the single administration dose meets clinical requirements (e.g., 1.28mg per spray).
Quality Control and Stability
Critical Quality Attribute (CQA) Testing
Purity:
HPLC testing shows that individual impurity ≤ 0.8% and total impurity ≤ 1.5%.
Content uniformity:
The content deviation per spray ≤ ±10%.
Microbial limit:
Total aerobic microbial count ≤ 750 CFU/g; Escherichia coli and Salmonella shall not be detected.
Stability Studies
Long-term stability:
The powder form can be stored at -20℃ for 3 years and at 4℃ for 2 years; the solution form can be stored at -80℃ for 6 months and at -20℃ for 1 month.
Accelerated testing:
Place Tesamorelin Spray at 40℃/75%RH for 6 months, and verify whether the changes in content, impurities, and pH comply with the standards.
Packaging and Transportation
Packaging Materials
Primary packaging:
Brown glass bottles or high-density polyethylene (HDPE) bottles are used to protect the drug activity from light.
Secondary packaging:
Aluminum foil bags or foam boxes are used, with ice packs inside to maintain a low-temperature environment (2–8℃) and prevent degradation caused by temperature fluctuations during transportation.
Transportation Conditions
Cold chain logistics is required for transportation to ensure that the temperature is controlled at 2–8℃ throughout the process, avoiding freezing or exposure to high temperatures.
A temperature recorder must be equipped during transportation to monitor temperature data in real time and ensure traceability.
Manufacturing Challenges and Solutions
| Manufacturing Challenges | Solutions |
|---|---|
| Low nasal mucosal absorption efficiency | Optimize the type and concentration of penetration enhancers (e.g., 0.05%–0.1% polysorbate 80), and combine microemulsion technology to form nano-scale drug-loaded particles for improved transdermal efficiency. |
| Risk of drug degradation | Add antioxidants (e.g., 0.01% EDTA) and metal chelators to inhibit oxidation reactions; adopt nitrogen displacement packaging to reduce contact with oxygen. |
| Control of dosage accuracy | Adopt quantitative valve systems (e.g., VP3 or VP7 valves) combined with online weighing detection to ensure that the dosage deviation per spray ≤ ±5%. |
FAQ
How does it make you feel?
+
-
This medicine may cause swelling (fluid retention) in some parts of your body. Check with your doctor right away if you have an increase in joint pain, or numbness or tingling sensations in your hands or wrist. Tesamorelin injection may cause changes in your blood sugar levels.
How effective is tesamorelin for fat loss?
+
-
At 26 weeks, it reduced deep belly fat by 13% compared to placebo. At 52 weeks, for those who continued on the drug, tesamorelin reduced it by nearly 18%.
Hot Tags: tesamorelin spray, China tesamorelin spray manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, best hcg supplement, glp1 shot, etelcalcetide structure
